

Supplementary Table 6 Follow-up Results

Characteristics	Targeted-first (32)	Radiotherapy-first (56)
iPFS		
iPFS(%)	53.1(17/32)	48.2(27/56)
Time to iPFS Failure(range) (mo)	1.1-31.8	0.9-43.1
Median(mo)	13.4 (95%: 6.860-20.000)	15.6 (95%: 7.700-23.500)
iPFS at 6 months (%)	66.1 (95%: 47.700-84.500)	87.1 (95%: 77.300-96.900)
iPFS at 12 months (%)	45.1 (95%: 23.700-66.500)	53.5 (95%: 36.600-70.400)
OS		
OS (%)	43.75(14/32)	39.29(22/56)
Follow up time (months)	1.5-50.5	2.1-65.1
Median (range) (mo)	17.9 (95%: 13.400-26.000)	23.5 (95%: 14.700-32.300)
Overall Survival at 6 months (%)	80.3 (95%:66.200-94.400)	85.5 (95%:76.100-94.900)
Overall Survival at 12 months (%)	67.7 (95%:49.900-85.500)	70.8 (95%:58.300-83.300)
Overall Survival at 24 months (%)	28.7 (95%:8.300-49.100)	46.4 (95%:31.700-61.100)
Local Control		
Local Control (%)	76.0(73/96)	80.7(267/331)
Time to Local Failure(range) (mo)	1.2-13.4	0.9-43.1
Median (mo)	NR	23.8 (95%: 15.2-32.5)
Local Control at 6 months (%)	73.6 (95%:62.200-84.900)	94.9 (95%:92.200-97.600)
Local Control at 12 months (%)	51.6 (95%:34.400-68.800)	78.7 (95%:72.000-85.400)
New Lesion		
New Lesion(s) (%)	34.38(11/32)	42.86(24/56)
Time to New Lesion(s) (range) (mo)	1.1-31.8	0.9-43.1
Median (mo)	17.4 (95%: 2.400-32.400)	18.1 (95%: 14.400-21.700)
No New Lesion & Survival at 6 months (%)	68.6 (95%:50.200-87.000)	89.2 (95%:80.200-98.200)
No New Lesion & Survival at 12 months (%)	60.1 (95%:37.600-82.600)	66.5 (95%:50.200-82.800)